Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy versus imiquimod for lentigo maligna
ACTRN12615000266561Phase 3Completed
- Sponsor
- Melanoma and Skin Cancer Trials
- Start
- Aug 2015
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of imiquimod in lentigo maligna (LM) (2 arms), sponsored by Melanoma and Skin Cancer Trials. Primary endpoint: Biopsy-confirmed lentigo maligna treatment failure. Started Aug 2015; status: completed.
02
Drugs
imiquimod
03
Conditions
lentigo maligna (LM)
Beyond the preview
Go deeper on ACTRN12615000266561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000266561.